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Treatment of patients with acute myeloid leukemia, medically fit to receive 
intensive chemotherapy, has been standardized over the past four decades and 
consists of an anthracycline administered along with continuous cytarabine. This 
combination is traditionally administered as seven days of cytarabine and three 
days of anthracycline, known as 7 + 3. Selecting the appropriate choice and dose of 
anthracycline for induction chemotherapy continues to be debated. Daunorubicin, 
used in three doses of either 45 mg/m2, 60 mg/m2 or 90 mg/m2, and idarubicin 
12 mg/m2 are the two commonly used anthracyclines in clinical practice. Other 
anthracyclines including mitoxantrone and liposomal daunorubicin are incor-
porated in the treatment algorithm as well. Our understanding of the underlying 
biology of acute myeloid leukemia has significantly increased in the past decade, 
helping us formulate individualized treatment plans. In this chapter, we will discuss 
pivotal studies comparing the safety and efficacy of different types and doses of 
anthracyclines, focusing predominantly on daunorubicin and idarubicin. The details 
of the study design as well as subgroup analysis will be presented to determine which 
subset of patients with AML may benefit from a particular anthracycline.
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1. Introduction
Acute Myeloid Leukemia (AML) is a heterogenous clonal stem cell disorder, 
resulting in proliferation of immature hematopoietic cells in the bone marrow, 
peripheral blood and occasionally in other tissues. Consequentially, normal hema-
topoiesis is inhibited, resulting in neutropenia, anemia and thrombocytopenia. 
Patients usually present with signs and symptoms of underlying bone marrow 
failure including fatigue, lethargy, shortness of breath, bruising, bleeding and 
infections [1–3].
The incidence rate of AML increases progressively with advancing age. It is 
primarily a disease of the elderly with the median age at diagnosis being 68 years 
and accounts for 80–90% of all acute leukemias in adults. There are approximately 
20,000 new cases of AML diagnosed every year in the United States, accompanied 
by nearly 10,000 deaths [1, 3, 4].
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Our understanding of the molecular pathogenesis of AML has increased signifi-
cantly in the last decade. Unfortunately, this understanding has not been matched 
in terms of therapeutic advances, though this has slowly changed since 2017. Age, 
cytogenetics and molecular aberrations play a significant role in determining 
prognosis as well as choice of treatment in patients with AML [2, 5, 6].
Treatment of AML can broadly be divided into intensive and non-intensive 
chemotherapy. Currently, in addition to age, performance status and medical 
fitness influence intensity of treatment. Traditionally, young and medically fit 
patients are treated with an intensive chemotherapy regimen. An arbitrary cutoff 
of 55 to 65 years has commonly been used to define ‘older’ and ‘younger’ patients. 
Medical fitness can be determined relatively accurately by assessing variables 
including performance status, organ function and frailty. A combination of age 
and medical fitness routinely form the basis for the assignment to the intensity of 
treatment [7–12].
Intensive chemotherapy generally involves a remission induction phase, to 
achieve complete remission, followed by a post-remission or consolidation phase, 
to stay in remission and prevent relapse. A combination of an anthracycline and 
cytarabine is almost always used as upfront intensive therapy for patients with 
AML. Nearly four decades ago, 7 days of cytarabine and 3 days of daunorubicin was 
established as the standard of care for patients with AML. Even today, this regimen, 
commonly known as 7 + 3, serves as the backbone in the treatment algorithm for 
AML. Since the 1970s, many trials have attempted to improve upon this combina-
tion either by using different doses of anthracyclines, different types of anthracy-
clines or adding a third agent. With very few exceptions, 7 + 3 remains standard of 
care outside of clinical trials [13, 14].
To this day, it is not entirely clear which type and dose of anthracycline is ideal 
when used during induction chemotherapy. Daunorubicin and idarubicin have been 
compared extensively in randomized studies. Mitoxantrone is also considered at 
times. CPX-351 (liposomal daunorubicin:cytarabine) is FDA approved, as induction 
therapy, in a subset of patients with AML.
In this chapter, we will present the data comparing the different types and doses 
of anthracyclines used in induction chemotherapy. Whereas details on all agents 
will be provided, the main focus will revolve around daunorubicin (45 mg/m2, 
60 mg/m2 and 90 mg/m2) and idarubicin (mainly 12 mg/m2) since they are the most 
commonly used anthracyclines. Furthermore, randomized studies where induction 
chemotherapy was not given in a 7 + 3 manner have also been discussed.
2. Daunorubicin
Daunorubicin, a topoisomerase II inhibitor, inhibits both DNA and RNA 
synthesis by intercalating between DNA base pairs, inhibiting transcription by 
inhibiting DNA-dependent RNA polymerase as well as steric obstruction. It was 
discovered as an antitumor antibiotic in the 1960s and has since been used as part 
of the treatment algorithm for AML [15]. In 1973, Yates et al. shared their findings 
of using 7 days of continuous cytarabine infusion and 3 days of daunorubicin in 
patients with AML. They reported a complete remission rate of 63% in 8 untreated 
patients with AML. The superiority of this regimen was confirmed by CALGB 7421, 
a trial comparing 7 + 3 to 5 days of continuous cytarabine infusion and 2 days of 
anthracycline (5 + 2) [13, 14]. Thus, 7 + 3 became the backbone of AML treatment 
for the next four decades and remains the standard to which other therapies are 
compared to even today.
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The dose of daunorubicin used by Yates et al. as well as CALGB 7421 was 45 mg/m2 
and this dose was used as standard going forward after confirmatory results of CALGB 
7721. Since then, several attempts have been made to modify the dose of daunorubicin, 
as part of standard induction therapy, to further improve outcomes of patients with 
AML [6, 16–19].
2.1 Daunorubicin 45 mg/m2 vs. 90 mg/m2
2.1.1 Older adults
A HOVON-SAKK-AMLSG collaboration investigated escalated daunorubicin 
dose (90 mg/m2) vs. standard daunorubicin dose (45 mg/m2) with 200 mg/m2 of 
cytarabine continuous infusion (7 + 3) in older adults with AML [20]. The study 
enrolled 813 patients with a median follow-up of 40 months. The median age of the 
study population was 67 years (range 60–83). Around 60% of the study population 
had intermediate-risk cytogenetics. All patients received a second cycle of cytara-
bine at a dose of 1000 mg/m2, every 12 hours, for 6 days.
The escalated dose was associated with higher rates of complete remission when 
compared to standard dose (64% vs. 54%, p = 0.002) as well as higher rates of 
complete remission after first cycle of induction (52% vs. 35%, p < 0.001). There 
were no significant differences in terms of toxicities and early mortality between 
the 2 doses. For the overall population, there was no difference in overall survival, 
event-free survival and disease-free survival between the 2 doses. In a subset 
analysis of patients between the ages of 60 and 65, the escalated dose was associ-
ated with higher rates of complete remission, event-free survival (29% vs. 14%) 
and overall survival (38% vs. 23%). Within the limitations of the small numbers, 
older patients with core-binding factors abnormalities also seemed to derive 
survival benefit with the escalated dose.
2.1.2 Younger adults
In ECOG 1900, Fernandez et al. investigated 3 days of high dose daunorubicin 
at 90 mg/m2 vs. standard dose daunorubicin at 45 mg/m2, in combination with 
100 mg/m2 of cytarabine as continuous infusion (7 + 3), in young patients with 
AML [21]. The study enrolled 657 patients with a median age of 48 years (range 
17–60). A second round of induction was given to patients with residual disease 
on day 14 bone marrow biopsy. The regimen was 7 + 3 with a daunorubicin dose of 
45 mg/m2. Approximately 41% of the patients had intermediate-risk cytogenetics 
and 14% and 19% had favorable and unfavorable-risk cytogenetics, respectively.
The rates of complete remission were higher with high dose daunorubicin 
compared to standard dose (70.6% vs. 57.3%, p < 0.001). The rates of complete 
remission after first induction were also higher in the high dose arm (83.3% vs. 
72%). There was no difference in early mortality between the 2 doses. High dose 
daunorubicin was associated with a higher 4-year overall survival (39% vs. 31%, 
p = 0.001), median overall survival (25.4 m vs. 16.6 m, p = 0.001) and event-free 
survival (28% vs. 20%, p < 0.001). Subgroup analysis demonstrated that patients 
younger than 50 years benefit significantly with high dose daunorubicin with 
higher complete remission rates (74.3% vs. 59.4%) and improved survival (median 
overall survival: 34.3 m vs. 19.0 m, HR 0.65, p = 0.004). The benefit of high dose 
daunorubicin did not extend to patients ≥50 years.
Survival with high dose daunorubicin was numerically longer, but statistically 
insignificant, in patients with favorable-risk cytogenetics, when compared to 
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standard dose. Patients with intermediate-risk cytogenetics benefitted from high 
dose daunorubicin, compared to standard dose, with a median overall survival of 
32.3 m vs. 17.8 m (HR 0.67, p = 0.02). There was no difference in survival between 
the 2 doses for patients with unfavorable cytogenetics as well as those with FLT3-ITD 
or MLL-PTD mutations.
An updated report of ECOG 1900 was presented in 2016 with a longer follow-up 
time period (median 80.1 months amongst survivors) [22]. The update confirmed 
the benefit of high dose daunorubicin in patients younger than 50 years of age 
(44.7 m vs. 20.7 m, 9 = 0.002). Older patients did not gain survival advantage with 
the high dose.
The benefit of high dose daunorubicin, compared to standard dose, was shown 
in patients with both favorable (NR vs. 39.4 m, HR 0.51, p = 0.03) and intermediate-
risk cytogenetics (33.5 m vs. 20.1 m, HR 0.68, p = 0.01). After controlling for 
confounding variables, a benefit for patients with unfavorable-risk cytogenetics was 
also seen with the high dose (HR 0.66, p = 0.04).
Subset analysis based on molecular subgroups revealed that FLT3-ITD, 
DNMT3A and NPM1 mutant-AML derived benefit from high dose daunorubicin. 
Patients with FLT3-ITD mutated AML had a 4-year overall survival of 28% with 
high dose daunorubicin compared to 17% with standard dose. The data suggests 
that an additional 10% of patients with FLT3-ITD mutated AML can be cured 
with the higher dose. Further analysis demonstrated that both younger and older 
patients with FLT3-ITD mutant AML derived benefit from high dose daunorubi-
cin. Patients with DNMT3A mutant AML had longer median overall survival with 
high dose daunorubicin, compared to standard dose (16.5 m vs. 14.1 m). However, 
the benefit of high dose daunorubicin, in DNMT3A mutant AML, was limited to 
patients younger than 50 years of age. Both younger and older patients with NPM1 
mutant AML derived benefit with high dose daunorubicin. The median overall 
survival with high dose daunorubicin was 75.9 months, compared to 16.9 months 
with standard dose. The 4-year overall survival increased with high dose daunoru-
bicin to 52% from 29% with standard dose.
Another phase III study compared high dose daunorubicin at 90 mg/m2 for 
3 days with standard dose daunorubicin at 45 mg/m2 for 3 days, in addition to 
cytarabine 200 mg/m2 as continuous infusion, in adults ≤60 years of age with 
AML [23]. The study enrolled 383 patients. A second round of abbreviated induc-
tion was given to patients with residual disease on day 14 bone marrow biopsy. 
Approximately 62% of the patients had intermediate-risk cytogenetics and 21% and 
15% had favorable and unfavorable-risk cytogenetics, respectively.
The rates of complete remission were higher with daunorubicin 90 mg/m2 when 
compared to 45 mg/m2 (82.5% vs. 72.0%, p = 0.014). After a median follow-up of 
52.6 months, high dose daunorubicin, compared to standard dose, was associated 
with improved overall survival (46.8% vs. 34.6%, p = 0.03) and event-free survival 
(40.8% vs. 28.4%, p = 0.03). There was no difference in the toxicity profile in 
both arms. In multivariable analysis, high dose daunorubicin was associated with 
higher complete remission rate (HR, 1.802, P = 0.024), improved overall survival 
(HR, 0.739, P = 0.032) and event-free survival (HR, 0.774, P = 0.04). Based on 
cytogenetic risk group, the benefit was of high dose daunorubicin was mainly seen 
in patients with intermediate risk disease. Molecular subgroup analysis was not 
available.
2.2 Daunorubicin 45 mg/m2 vs. 60 mg/m2
There is no randomized data comparing daunorubicin 60 mg/m2 to dauno-
rubicin 45 mg/m2. One retrospective study evaluated 56 patients and reported 
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complete remission rates of 88% with daunorubicin 60 mg/m2 and 67% with 
daunorubicin 45 mg/m2 (p = 0.05). Details on disease-free and overall survival 
were not available [24].
2.3 Daunorubicin 60 mg/m2 vs. 90 mg/m2
The UK NCRI AML17 trial compared daunorubicin 60 mg/m2 to 90 mg/m2 in 
AML induction [25]. The induction chemotherapy regimen was not administered as 
standard 7 + 3 and used a modified strategy of giving the anthracycline on days 1, 3 
and 5, in combination with cytarabine 100 mg/m2, every 12 hours, on days 1 to 10. 
Furthermore, a second round of induction was given to all patients in morphological 
remission after the first induction and consisted of daunorubicin 50 mg/m2 on days 
1, 3 and 5 and cytarabine 100 mg/m2, every 12 hours, on days 1–8. Hence the cumu-
lative dose of daunorubicin in the 90 mg/m2 and 60 mg/m2 arms was 420 mg/m2 
and 330 mg/m2, respectively. The cumulative dose for both doses, if used in a 7 + 3 
regimen, would have been 270 mg/m2 and 180 mg/m2, respectively.
The study enrolled 1206 patients with a median age of 53 years (range 
16–72 years). Nearly three fourths of the patients in the study had intermediate 
risk cytogenetics. After a median follow-up of 14.8 months, the study was termi-
nated prematurely due to higher risk of mortality by day 60 in the daunorubicin 
90 mg/m2 arm, with an intention-to-treat analysis showing no benefit of the 
higher dose. There was no difference in the rate of complete remission between 
the 2 arms (D60 75% vs. D90 73%, p = 0.6). There was no difference in 30-day 
mortality between the 2 arms, but 60-day mortality was higher with daunoru-
bicin 90 mg/m2, compared to 60 mg/m2 (10% vs. 5%, p = 0.001). Furthermore, 
there was no statistical difference between the 2 arms in terms of overall survival 
(D60 60% vs. D90 59%, p = 0.15), relapse-free survival (D60 48% vs., D90 51%, 
p = 0.7) and 2-year overall survival censored at stem cell transplant (D60 60% vs. 
D90 60%). An exploratory analysis did not identify any subgroup that benefited 
with the higher dose of daunorubicin.
An updated intention-to-treat analysis, after a median follow-up of 28 months, 
revealed no differences in terms of rates of complete remission, overall survival, 
and relapse-free survival [26]. However, subgroup analysis indicated that the 
higher dose of daunorubicin may benefit patients with FLT3-ITD mutant AML, 
(Cumulative incidence of relapse: 44% vs. 60%; HR, 0.58; p = .01; RFS: 45% vs. 
33%; HR, 0.63; p = .02; OS: 54% vs. 34%; HR, 0.65; p = .03). The survival benefit 
seemed to be independent of the allelic burden of the mutation as well as coexisting 
NPM1 mutations.
Data from the DaunoDouble trial were recently presented at the European 
Hematology Association in the form on an abstract [27]. The trial compared dau-
norubicin 60 mg/m2 to daunorubicin 90 mg/m2 when given as 7 + 3. Daunorubicin 
was given on days 3 to 5. The study enrolled 262 patients and the median age of the 
population was 52 years. Per the European Leukemia Network 2017 classification, 
there were 39% patients with favorable, 40% with intermediate and 21% with 
adverse risk disease. Response assessment was based on a day 15 bone marrow 
and patients with <5% blasts were further randomized to either receive a second 
induction with 7 + 3 or to no further induction. The results of the second random-
ization are not yet available. The rate of remission with a maximum of two rounds 
of induction was 67% with daunorubicin 60 mg/m2 and 61% with daunorubicin 
90 mg/m2 (p = 0.32). With a median follow-up of 40 months, there was no differ-
ence in cumulative incidence of relapse (p = 0.343) and treatment related mortality 
(p = 0.994). There was no difference in 4-year overall survival (p = 0.108), event-
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Complete data not available
D90: daunorubicin 90 mg/m2, D60: daunorubicin 60 mg/m2, D45: daunorubicin 45 mg/m2, 7 + 3: 7 days of cytarabine and 3 days of anthracycline, CR: complete remission, EFS: event-free survival, OS: 
overall survival.
Table 1. 
Summary of trials comparing different doses of daunorubicin.
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there was no difference in outcomes based on daunorubicin dose on multivariable 
analysis. Although these results support the use of daunorubicin 60 mg/m2, results 
from the second randomization in the study will facilitate with data interpretation.
A summary of the trials comparing different doses of daunorubicin is presented 
in Table 1.
2.4 FLT3-mutant AML
A randomized study compared the addition of midostaurin, a multitarget kinase 
inhibitor, or placebo to 7 + 3 in FLT3 mutated AML. The dose of daunorubicin was 
60 mg/m2 and patients were < 60 years of age. Compared to placebo, the addition 
of midostaurin prolonged overall and event-free survival in this population [18]. 
Whether using daunorubicin 90 mg/m2 or idarubicin would have yielded even 
better results remain unknow. There is data (discussed below) that daunorubicin 
90 mg/m2 may be the optimal choice to use in FLT3 mutated AML.
3. Idarubicin
3.1 Idarubicin 12 mg/m2 vs. daunorubicin 45 mg/m2
Idarubicin was introduced into the treatment of AML, as a newer anthracycline, 
in the 1990s. Four trials during that time compared idarubicin 12–13 mg/m2 for 
3 days to daunorubicin 45–50 mg/m2 for 3 days, given with cytarabine as induction 
chemotherapy for AML. Three of those studies found idarubicin to be superior to 
daunorubicin and there was a signal of rapid response to idarubicin, compared to 
daunorubicin, in the fourth study [28–31]. Another study compared daunorubicin 
50 mg/m2 for 3 days to idarubicin 8 mg/m2 for 5 days, given with seven days of 
cytarabine, and found idarubicin to be more effective than daunorubicin in AML 
patients between 55 and 75 years of age [32]. In summary, idarubicin at an average 
dose of 12 mg/m2 is most likely superior to daunorubicin 45 mg/m2, when adminis-
tered with cytarabine as induction chemotherapy.
3.2 Idarubicin vs. high dose daunorubicin
3.2.1 Idarubicin 12 mg/m2 vs. daunorubicin 90 mg/m2
Since idarubicin was found to be superior to standard dose daunorubicin 
(45 mg/m2), the next obvious comparison was between idarubicin and high dose 
daunorubicin. Studies that compare idarubicin to dose intensified daunorubicin 
delivered as either higher daily doses or prolonged administration of the standard 
dose have been conducted. In general, regimens with dose intensified daunorubicin 
have targeted to achieve a cumulative dose of 240–280 mg/m2 during induction. Key 
prospective randomized studies comparing these strategies are summarized here.
A Phase III randomized, noninferiority study conducted in South Korea was 
reported in 2017 [33]. There were 299 patients with a median age of 49 years (range 
15–65). They were randomized to receive infusional cytarabine 200 mg/m2 for 7 days 
with either idarubicin 12 mg/m2 or daunorubicin 90 mg/m2 for 3 days. If Day 14 
bone marrow assessment revealed persistent disease, patients received an additional 
round of induction with infusional cytarabine for 5 days plus idarubicin 8 mg/m2 
or daunorubicin 45 mg/m2. Patients received consolidation therapy followed by 
transplantation (either allogeneic or autologous) in first remission based on their 
cytogenetic risk stratification and donor availability. There was a higher proportion 
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of secondary (4.7% vs. 11.3%), poor risk (14.5% vs. 27.5%) and good risk (18.6% 
vs. 23.5%) disease in the daunorubicin arm, while more intermediate risk disease 
(66.9% vs. 49%) was present in the idarubicin arm. These differences did not have 
significant impact on outcomes. Other baseline characteristics as well as post remis-
sion therapies received were similar between the two treatment arms.
In this study, rates of complete remission (80.5% v 74.7%; P = .224), 4-year 
overall survival (51.1% vs. 54.7%, p = 0.756), cumulative incidence of relapse 
(35.2% v 25.1%; P = .194) and event-free survival (45.5% v 50.8%; p = 0.772) did 
not differ between the idarubicin and daunorubicin arms, respectively. However, 
in the subgroup analysis of FLT3-ITD-mutant AML (n = 44; idarubicin n = 27; 
daunorubicin n = 17) the median overall survival (not reached vs. 15.2 m, p = 0.03) 
and event-free survival (not reached vs. 11.9 m, p = 0.03) favored the daunorubi-
cin arm, while remission rates were similar (88.2% vs. 74.1%) in both groups. No 
differences were noted in the non FLT3-ITD-mutant subgroup. Adverse events were 
similar between both groups.
In summary, this study showed noninferiority of high dose daunorubicin 
compared to standard dose idarubicin. There is a suggestion that high dose dau-
norubicin improved survival, but not remission rate, in FLT3-ITD-mutant AML. 
However, the study was not powered adequately to draw definitive conclusions in 
this subgroup analysis.
3.2.2 Idarubicin 12 mg/m2 vs. daunorubicin 50 mg/m2 (over 5 days)
The JASLG AML 201 phase III randomized, noninferiority study compared 
standard dose idarubicin to high dose daunorubicin defined as 50 mg/m2 over 5 days 
(as opposed to 90 mg/m2 over 3 days) [34]. This study had a second phase of ran-
domization for consolidation therapy after complete remission was attained. There 
were 1057 patients, with a median age of 47 years (range 14–65), randomized in the 
first phase to receive infusional cytarabine 100 mg/m2 for 7 days plus idarubicin 
or daunorubicin at the above-mentioned doses. Baseline characteristics were well 
balanced between the two groups. In this study, overall complete remission rate was 
77.9% and did not differ between the idarubicin (78.2%) and daunorubicin (77.5%) 
arms, establishing non-inferiority of high dose daunorubicin. Furthermore, 64.1% 
vs. 61.1% of patients achieved a CR after the first round of induction in the idaru-
bicin and daunorubicin arms, respectively. There was no difference in overall and 
relapse-free survival between the 2 arms.
3.2.3 Idarubicin 12 mg/m2 vs. daunorubicin 80 mg/m2
ALFA 9801, a randomized study, compared daunorubicin 80 mg/m2 for 3 days 
to standard dose idarubicin 12 mg/m2 (IDA3) in patients aged 50–70 years. A third 
arm of idarubicin 12 mg/m2 for 4 days (IDA4) was also added [35]. Patients who 
had residual disease on a day 20 bone marrow assessment could receive additional 
induction with a pre-specified mitoxantrone based regimen. Those who achieved 
complete remission then received 2 cycles of consolidation with intermediate dose 
cytarabine + anthracycline based on their randomization group. This study had a 
second phase of randomization which investigated the role of recombinant IL-2 
in maintenance therapy, which will not be discussed in this chapter. Four hundred 
and seventy-eight patients underwent the first phase of randomization and baseline 
characteristics were well balanced in the three arms. Overall complete remis-
sion rate was found to be lower in the daunorubicin arm (70%) compared to the 
IDA3 (83%) or IDA4 (78%) arms and this difference was statistically significant. 
However, there was no difference in remission rates after the first induction therapy. 
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No significant difference was noted in the secondary outcomes of event-free 
survival, overall survival, and cumulative incidence of relapse between the three 
arms. Induction related deaths, cytopenias and duration of hospitalization was also 
similar between the groups. Thus, in this older population of AML patients, while 
the overall complete remission rates appear to be higher in the idarubicin group, no 
differences were noted in remission after first induction, overall survival or event-
free survival.
3.2.4 Idarubicin 8 mg/m2 (5 days) vs. daunorubicin 60 mg/m2
Another trial comparing idarubicin to high dose daunorubicin based induction 
was the phase III GOELAMS LAM-2001 trial, which included patients between 
the ages of 17–60 years [36]. The study was primarily designed to compare single 
vs. tandem autologous hematopoietic stem cell transplant strategies as post remis-
sion therapy, however the initial phase randomized 832 patients to receive either 
idarubicin or daunorubicin based induction. The induction regimen used here 
was infusional cytarabine 200 mg/m2 for 7 days plus either idarubicin 8 mg/m2 for 
5 days (cumulative dose of 40 mg/m2 during induction) or daunorubicin 60 mg/
m2 for 3 days. This study revealed similar complete remission rates between the two 
groups (83% vs. 81%). Seven-year long term follow up of the patients randomized 
in the first phase of the study was reported in 2013, looking at a variety of cox pro-
portional models to account for interactions with the second randomization arm. 
Patients in the idarubicin arm had an improved 7-year OS, compared to daunoru-
bicin, unless they had unfavorable cytogenetics. A subset analysis of patients with 
intermediate risk cytogenetics (n = 393) demonstrated improved 7-year overall 
survival (p = 0.005) as well as event-free survival (p = 0.025) with idarubicin [37].
3.2.5 Idarubicin 9 mg/m2 (4 days) vs. daunorubicin 45 mg/m2 (4 days)
ALFA 9803 was designed to compare two different post-remission strategies 
but included a first phase of randomization comparing idarubicin to daunorubicin. 
There were 416 patients aged 65 years or older, randomized to receive infusional 
cytarabine for 7 days, with either daunorubicin 45 mg/m2 for 4 days (cumulative 
dose 180 mg/m2) or idarubicin 9 mg/m2 for 4 days (36 mg/m2). There was no  
difference in complete remission rates or toxicity profiles between the two induc-
tion strategies [38].
Finally, combined long term outcomes of patients enrolled in the ALFA 9801 
and 9803 studies have been reported to identify factors associated with improved 
long-term survival. This report interestingly revealed randomization to idarubicin 
to be associated with an improved cure rate (16.6% vs. 9.8%), although standard 
survival analysis in the independent trials did not reveal any differences between 
idarubicin and daunorubicin based induction [39].
3.2.6 Idarubicin 12 mg/m2 vs. daunorubicin 60 mg/m2
There is no randomized or retrospective data comparing idarubicin 12 mg/m2 to 
daunorubicin 60 mg/m2, when administered with continuous cytarabine as 7 + 3. 
Both these doses are frequently used interchangeably in clinical trials but whether 
their efficacy is equivalent is not well defined.
Two meta-analysis compared the efficacy of idarubicin to daunorubicin. One 
focused on high dose daunorubicin only and found that idarubicin was associ-
ated with higher rates of complete remission and lower rates of refractory disease 
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D90: daunorubicin 90 mg/m2, D80: daunorubicin 80 mg/m2, D60: daunorubicin 60 mg/m2, D50: daunorubicin 50 mg/m2, D45: daunorubicin 45 mg/m2, Ida12: idarubicin 12 mg/m2, Ida8: idarubicin 
8 mg/m2, Ida9: idarubicin 9 mg/m2, 7 + 3: 7 days of cytarabine and 3 days of anthracycline, CR: complete remission, EFS: event-free survival, OS: overall survival.
Table 2. 
Summary of trials comparing idarubicin and daunorubicin.
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neutropenia, cardiotoxicity and overall survival between the 2 drugs. The second 
study also showed that idarubicin was associated with improved rates of complete 
remission as well as overall survival, compared to daunorubicin [16, 40].
A summary of the trials comparing idarubicin and high dose daunorubicin is 
presented in Table 2.
4. Mitoxantrone
Mitoxantrone, an anthraquinone derivative, has been extensively used with 
cytarabine as part of induction chemotherapy in patients with AML. It has been 
shown to be equally effective, if not better, when compared to daunorubicin. 
Nonetheless, it has not been adapted readily into the clinical practice of upfront 
induction chemotherapy and is often incorporated into the treatment algorithm in 
the relapse and refractory setting. There are 2 randomized trials comparing mito-
xantrone, idarubicin and daunorubicin which will be discussed in the subsequent 
section.
The AML-10 study was a randomized phase III study comparing daunorubicin, 
idarubicin and mitoxantrone in 2157 patients, ≤60 years of age, with AML [41]. 
Remission induction was not given in the traditional 7 + 3 manner and consisted of 
cytarabine 100 mg/m2 on days 1–10, etoposide 100 mg/m2 on days 1–5 and either 
daunorubicin 50 mg/m2, idarubicin 10 mg/m2 or mitoxantrone 12 mg/m2 on days 
1, 3 and 5. A second round of the same regimen was given to those with a partial 
remission to the first round.
There was no difference in the rate of complete remission between the 3 anthra-
cyclines. Nearly a quarter of patients, in each arm, proceeded to allogeneic stem cell 
transplant. After a median follow-up of 5.6 years, there was no difference in median 
and 5-year overall survival between the 3 arms. Even after adjusting for other 
variables, the results remained the same. For patients without a donor, the disease-
free survival and survival from complete remission were longer in the idarubicin 
and mitoxantrone arm than in the daunorubicin arm. There was no difference for 
patients with a donor.
An ECOG phase III compared daunorubicin 45 mg/m2, idarubicin 12 mg/m2 and 
mitoxantrone 12 mg/m2, given with continuous cytarabine, as 7 + 3 in older adults 
with AML [42]. The study enrolled 362 patients with a median age of 67 years. A 
second round of the same induction was given to patients with residual disease 
(>5% blasts) on day 14 bone marrow biopsy. There was no statistically significant 
difference for the rates of complete remission between the 3 arms. Furthermore, 
there was no difference observed in terms of toxicity profile, disease-free survival 
and overall survival between the 3 induction regimens.
5. CPX-351 (Vyxeos)
CPX-351 is a liposomal encapsulation of cytarabine and daunorubicin at a fixed 
synergistic molar ratio of 5:1. Using ratio-metric dosing, instead of the traditionally 
used maximum tolerated dose (MTD), potentially enhances the efficacy of drugs 
by maintaining the fixed drug ratio for a longer time in the blood. In the conven-
tional form (MTD), the blood concentration or ratio of the drug(s), after infusion, 
may change immediately depending on the individual agent’s pharmacokinetics, 
raising concern for inferior efficacy. A liposomal encapsulation, by evading first 
pass metabolism, may overcome this concern and lead to greater uptake by leu-
kemia cells. Through this mechanism, an increased cytotoxic effect of the drugs 
Acute Leukemias
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is observed, leading to prolonged myelosuppression, in addition to apoptosis of 
leukemia cells [43, 44].
The liposome of daunorubin:cytarabine 44 mg/m2:100 mg/m2 is FDA 
approved for the treatment of adults with therapy related AML or AML with 
myelodysplasia-related changes. A phase III study compared cytarabine + liposo-
mal daunorubicin (CPX-351, Vyxeos) to 7 + 3 (daunorubicin 60 mg/m2), in older 
patients (60–75 years) with secondary AML. The study enrolled 309 patients. 
CPX-351 was associated with a higher remission rate (47.7% vs. 33.3%, p = 0.016) 
as well as improved median overall survival (9.6 m vs. 5.9 m, HR 0.69, p = 0.003) 
compared to 7 + 3. There was no difference in early mortality between the two 
treatments. Prolonged neutropenia and thrombocytopenia were observed with 
CPX-351 [19].
Although the study above was limited to older patients, the FDA approved 
CPX-351 for all adults. The reason being that therapy related AML or AML with 
myelodysplasia-related changes are thought to be biologically aggressive subtypes, 
regardless of age. Whether CPX-351 is superior, in patients <60 years old, to 7 + 3 
using either daunorubicin 90 mg/m2 or idarubicin is not known. The results of 
ongoing studies in younger patients as well as planned clinical trials using CPX-351 
in combination with targeted therapy or immunotherapy should help identify 
additional subsets of patients that may derive benefit from this drug.
6. Conclusion
AML is a heterogenous disease and the treatment plan for every patient is 
different. Both patient and disease related variables help determine the appropriate 
treatment option for each case. It is challenging to state the outright superiority of 
one anthracycline over another, but some useful conclusions can be drawn from 
the evidence presented above.
When choosing between 45 mg/m2, 60 mg/m2 and 90 mg/m2 of daunorubicin, 
it is reasonable to look at patient age and cytogenetic and molecular abnormalities 
(if available in a timely manner), before picking one. Daunorubicin 45 mg/m2 
should be used for older patients >65 years of age based on the available evidence. 
It is probably safe and effective to use daunorubicin 60 mg/m2 in this age group, 
but unfortunately there is lack of randomized data to support one dose over the 
other. For patients younger than 65 years of age, daunorubicin 90 mg/m2 is supe-
rior to daunorubicin 45 mg/m2. All cytogenetic risk categories and FLT3, NPM1 
and DNMT3A-mutant AML seem to derive benefit from daunorubicin 90 mg/m2. 
However, data is emerging to suggest that daunorubicin 60 mg/m2 can effectively 
replace daunorubicin 90 mg/m2.
Idarubicin is superior to daunorubicin 45 mg/m2, when used as 7 + 3, in younger 
patients. It also appears to be as safe and effective as daunorubicin 90 mg/m2, except 
for FLT3-mutant AML where daunorubicin 90 mg/m2 may have a slight advantage. 
One caveat to the idarubicin vs. high dose daunorubicin studies is the small repre-
sentation of older patients (>65 years). For older patients fit for intensive therapy, 
daunorubicin 45 mg/m2, may still be the first choice.
Mitoxantrone is comparable to both idarubicin and daunorubicin. It’s use in 
upfront therapy is still not as common as the other 2 available agents. CPX-351 
should be the first choice in patients with secondary AML.
Whereas novel drug regimens are emerging in the treatment of AML, intensive 
chemotherapy still plays a significant role. Anthracyclines will serve as the back-
bone of AML treatment in fit patients and therefore it is important to know which 
type and dose to select in the appropriate setting.
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